308 related articles for article (PubMed ID: 24871807)
41. Low-level dystrophin expression attenuating the dystrophinopathy phenotype.
Waldrop MA; Gumienny F; El Husayni S; Frank DE; Weiss RB; Flanigan KM
Neuromuscul Disord; 2018 Feb; 28(2):116-121. PubMed ID: 29305136
[TBL] [Abstract][Full Text] [Related]
42. A
Echigoya Y; Trieu N; Duddy W; Moulton HM; Yin H; Partridge TA; Hoffman EP; Kornegay JN; Rohret FA; Rogers CS; Yokota T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884867
[TBL] [Abstract][Full Text] [Related]
43. Interplay between DMD point mutations and splicing signals in Dystrophinopathy phenotypes.
Juan-Mateu J; González-Quereda L; Rodríguez MJ; Verdura E; Lázaro K; Jou C; Nascimento A; Jiménez-Mallebrera C; Colomer J; Monges S; Lubieniecki F; Foncuberta ME; Pascual-Pascual SI; Molano J; Baiget M; Gallano P
PLoS One; 2013; 8(3):e59916. PubMed ID: 23536893
[TBL] [Abstract][Full Text] [Related]
44. Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping.
Madden HR; Fletcher S; Davis MR; Wilton SD
Hum Mutat; 2009 Jan; 30(1):22-8. PubMed ID: 18570328
[TBL] [Abstract][Full Text] [Related]
45. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
[TBL] [Abstract][Full Text] [Related]
46. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
Popplewell LJ; Malerba A; Dickson G
Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
[TBL] [Abstract][Full Text] [Related]
47. Neuronal SH-SY5Y cells use the C-dystrophin promoter coupled with exon 78 skipping and display multiple patterns of alternative splicing including two intronic insertion events.
Nishida A; Minegishi M; Takeuchi A; Awano H; Niba ET; Matsuo M
Hum Genet; 2015 Sep; 134(9):993-1001. PubMed ID: 26152642
[TBL] [Abstract][Full Text] [Related]
48. Exon-skipping events in candidates for clinical trials of morpholino.
Nakano S; Ozasa S; Yoshioka K; Fujii I; Mitsui K; Nomura K; Kosuge H; Endo F; Matsukura M; Kimura S
Pediatr Int; 2011 Aug; 53(4):524-9. PubMed ID: 21342350
[TBL] [Abstract][Full Text] [Related]
49. Exon skipping therapy for Duchenne muscular dystrophy.
Kole R; Krieg AM
Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936
[TBL] [Abstract][Full Text] [Related]
50. Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping.
Bertoni C; Lau C; Rando TA
Hum Mol Genet; 2003 May; 12(10):1087-99. PubMed ID: 12719373
[TBL] [Abstract][Full Text] [Related]
51. Rescue of dystrophin mRNA of Duchenne muscular dystrophy by inducing exon skipping.
Matsuo M; Takeshima Y
Acta Myol; 2005 Oct; 24(2):110-4. PubMed ID: 16550927
[TBL] [Abstract][Full Text] [Related]
52. Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.
Arechavala-Gomeza V; Anthony K; Morgan J; Muntoni F
Curr Gene Ther; 2012 Jun; 12(3):152-60. PubMed ID: 22533380
[TBL] [Abstract][Full Text] [Related]
53. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
54. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
[TBL] [Abstract][Full Text] [Related]
55. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
[TBL] [Abstract][Full Text] [Related]
56. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
57. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.
Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F
Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647
[TBL] [Abstract][Full Text] [Related]
58. Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy.
Beckers P; Caberg JH; Dideberg V; Dangouloff T; den Dunnen JT; Bours V; Servais L; Boemer F
Sci Rep; 2021 Feb; 11(1):3011. PubMed ID: 33542429
[TBL] [Abstract][Full Text] [Related]
59. A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures.
Hiller M; Falzarano MS; Garcia-Jimenez I; Sardone V; Verheul RC; Popplewell L; Anthony K; Ruiz-Del-Yerro E; Osman H; Goeman JJ; Mamchaoui K; Dickson G; Ferlini A; Muntoni F; Aartsma-Rus A; Arechavala-Gomeza V; Datson NA; Spitali P
PLoS One; 2018; 13(10):e0204485. PubMed ID: 30278058
[TBL] [Abstract][Full Text] [Related]
60. In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G-->A mutations in introns of the dystrophin gene.
Habara Y; Takeshima Y; Awano H; Okizuka Y; Zhang Z; Saiki K; Yagi M; Matsuo M
J Med Genet; 2009 Aug; 46(8):542-7. PubMed ID: 19001018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
